Literature DB >> 12908531

Laser treatment of zone I prethreshold and stage 3 threshold retinopathy of prematurity.

Zsuzsa Récsán1, Rita Vámos, György Salacz.   

Abstract

PURPOSE: To analyze the structural outcomes of zone I prethreshold and stage 3 threshold retinopathy of prematurity following laser ablation. PATIENTS AND METHODS: This nonrandomized observational case series evaluated 71 eyes of 36 infants who weighed less than 1,250 g at birth. Infants were treated at either prethreshold or threshold severity. The structural outcomes were compared using Fisher's exact test.
RESULTS: The structural outcome was favorable in 96% and 80% of the prethreshold and threshold groups, respectively (P = .069). When an unfavorable outcome was defined as dragging of the temporal vessels, the difference was significant (P = .0257).
CONCLUSION: Early treatment of zone I disease may result in a better structural outcome.

Entities:  

Mesh:

Year:  2003        PMID: 12908531     DOI: 10.3928/0191-3913-20030701-06

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  5 in total

1.  Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months.

Authors:  J Sahni; N V Subhedar; D Clark
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

2.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

Review 3.  The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.

Authors:  Shing Chuen Chow; Pun Yuet Lam; Wai Ching Lam; Nicholas Siu Kay Fung
Journal:  Eye (Lond)       Date:  2022-01-11       Impact factor: 4.456

4.  Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.

Authors:  William V Good
Journal:  Trans Am Ophthalmol Soc       Date:  2004

5.  Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity.

Authors:  Simona Delia Nicoară; Constanța Nascutzy; Cristina Cristian; Iulian Irimescu; Anne Claudia Ștefănuț; Gabriela Zaharie; Tudor Drugan
Journal:  J Ophthalmol       Date:  2015-09-27       Impact factor: 1.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.